616 related articles for article (PubMed ID: 29159043)
21. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
22. Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.
Hartley SL; Fleming V; Schworer EK; Peven J; Handen BL; Krinsky-McHale S; Hom C; Lee L; Tudorascu DL; Laymon C; Minhas D; Luo W; Cohen A; Zaman S; Ances BM; Mapstone M; Head E; Lai F; Rosas HD; Klunk W; Christian B;
J Alzheimers Dis; 2023; 95(1):213-225. PubMed ID: 37482997
[TBL] [Abstract][Full Text] [Related]
23. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
24. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
25. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.
Lowe VJ; Lundt ES; Albertson SM; Przybelski SA; Senjem ML; Parisi JE; Kantarci K; Boeve B; Jones DT; Knopman D; Jack CR; Dickson DW; Petersen RC; Murray ME
Alzheimers Dement; 2019 Jul; 15(7):927-939. PubMed ID: 31175025
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography.
Tripathi SM; Murray AD
Neuroscientist; 2022 Oct; 28(5):507-519. PubMed ID: 33660556
[TBL] [Abstract][Full Text] [Related]
27. Evaluating the association between brain atrophy, hypometabolism, and cognitive decline in Alzheimer's disease: a PET/MRI study.
Chen Y; Wang J; Cui C; Su Y; Jing D; Wu L; Liang P; Liang Z
Aging (Albany NY); 2021 Feb; 13(5):7228-7246. PubMed ID: 33640881
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
29. Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.
Doran E; Keator D; Head E; Phelan MJ; Kim R; Totoiu M; Barrio JR; Small GW; Potkin SG; Lott IT
J Alzheimers Dis; 2017; 56(2):459-470. PubMed ID: 27983553
[TBL] [Abstract][Full Text] [Related]
30. Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease.
Dukart J; Kherif F; Mueller K; Adaszewski S; Schroeter ML; Frackowiak RS; Draganski B;
PLoS Comput Biol; 2013 Apr; 9(4):e1002987. PubMed ID: 23592957
[TBL] [Abstract][Full Text] [Related]
31. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
Shokouhi S; Campbell D; Brill AB; Gwirtsman HE;
Brain Pathol; 2016 Sep; 26(5):664-71. PubMed ID: 27327527
[TBL] [Abstract][Full Text] [Related]
33. The common dementias: a pictorial review.
Bhogal P; Mahoney C; Graeme-Baker S; Roy A; Shah S; Fraioli F; Cowley P; Jäger HR
Eur Radiol; 2013 Dec; 23(12):3405-17. PubMed ID: 24081643
[TBL] [Abstract][Full Text] [Related]
34. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
Koychev I; Hofer M; Friedman N
J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
[TBL] [Abstract][Full Text] [Related]
35. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.
Sabbagh MN; Fleisher A; Chen K; Rogers J; Berk C; Reiman E; Pontecorvo M; Mintun M; Skovronsky D; Jacobson SA; Sue LI; Liebsack C; Charney AS; Cole L; Belden C; Beach TG
Arch Neurol; 2011 Nov; 68(11):1461-6. PubMed ID: 22084131
[TBL] [Abstract][Full Text] [Related]
37. Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism.
Benvenutto A; Giusiano B; Koric L; Gueriot C; Didic M; Felician O; Guye M; Guedj E; Ceccaldi M
J Alzheimers Dis; 2018; 65(4):1147-1157. PubMed ID: 30124446
[TBL] [Abstract][Full Text] [Related]
38. Correlation Between Brain 18F-AV45 and 18F-FDG PET Distribution Characteristics and Cognitive Function in Patients with Mild and Moderate Alzheimer's Disease.
Jing J; Zhang F; Zhao L; Xie J; Chen J; Zhong R; Zhang Y; Dong C
J Alzheimers Dis; 2021; 79(3):1317-1325. PubMed ID: 33427748
[TBL] [Abstract][Full Text] [Related]
39. Imaging discrepancies between magnetic resonance imaging and brain perfusion single-photon emission computed tomography in the diagnosis of Alzheimer's disease, and verification with amyloid positron emission tomography.
Yokoyama S; Kajiya Y; Yoshinaga T; Tani A; Hirano H
Psychogeriatrics; 2014 Jun; 14(2):110-7. PubMed ID: 24954834
[TBL] [Abstract][Full Text] [Related]
40. [Neuroimaging in Alzheimer's disease: a synthesis and a contribution to the understanding of physiopathological mechanisms].
Villain N; Chételat G; Desgranges B; Eustache F
Biol Aujourdhui; 2010; 204(2):145-58. PubMed ID: 20950559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
